Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -4560.82% is 85% below its 5-year average of -2460.94%, near the high end of its 5-year range (-81551.61%–24059.32%).
30.42% above its 12-month average of -6554.32%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -9064.53%.
NET PROFIT MARGIN
-4560.82%
NET PROFIT MARGIN AVG TTM
-6554.32%
NET PROFIT MARGIN AVG 3Y
-1148.58%
NET PROFIT MARGIN AVG 5Y
-2460.94%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+30.42%
CURRENT VS 3Y AVG
-297.08%
CURRENT VS 5Y AVG
-85.33%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-1302991.43%
vs the sector median at left
Humacyte, Inc.
Market Cap
$80.30M
Net Profit Margin
-4560.82%
TTM Avg
-6554.32%
3Y Avg
-1148.58%
5Y Avg
-2460.94%
Market Cap
$79.61M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$81.20M
Net Profit Margin
-430.43%
TTM Avg
-446.97%
3Y Avg
-347.08%
5Y Avg
-386.84%
Market Cap
$81.22M
Net Profit Margin
-1168.20%
TTM Avg
-1464.39%
3Y Avg
-946.48%
5Y Avg
-672.82%
Market Cap
$79.03M
Net Profit Margin
-648.32%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$78.59M
Net Profit Margin
-12.91%
TTM Avg
-907.67%
3Y Avg
-691.25%
5Y Avg
-536.96%
Market Cap
$82.29M
Net Profit Margin
57.57%
TTM Avg
-58.69%
3Y Avg
-51.95%
5Y Avg
-56.60%
Market Cap
$78.29M
Net Profit Margin
-47475.71%
TTM Avg
-41070.98%
3Y Avg
-27618.26%
5Y Avg
-38759.83%
Market Cap
$82.47M
Net Profit Margin
-7884.06%
TTM Avg
-7191.86%
3Y Avg
-8225.67%
5Y Avg
-7676.39%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humacyte, Inc. (HUMA) | $80.30M | -4560.82% | -6554.32% | -1148.58% | -2460.94% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | 0.00% | 0.00% | 0.00% | 0.00% |
| Nutriband Inc. (NTRB)vs › | $81.20M | -430.43% | -446.97% | -347.08% | -386.84% |
| MediciNova, Inc. (MNOV)vs › | $81.22M | -1168.20% | -1464.39% | -946.48% | -672.82% |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | -648.32% | 0.00% | 0.00% | 0.00% |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | -12.91% | -907.67% | -691.25% | -536.96% |
| LENSAR Inc (LNSR)vs › | $82.29M | 57.57% | -58.69% | -51.95% | -56.60% |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | -47475.71% | -41070.98% | -27618.26% | -38759.83% |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | -7884.06% | -7191.86% | -8225.67% | -7676.39% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-5271.7%
Net Profit Margin
-4560.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -9064.53% |
| 2026-03-31 | -3559.39% |
| 2025-12-31 | -5311.35% |
| 2025-09-30 | -2325.37% |
| 2025-06-30 | -12510.96% |
| 2025-03-31 | 7570.41% |
| 2024-12-31 | -289.71% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | -81551.61% |
| 2022-06-30 | 2833.82% |
| 2022-03-31 | -8511.59% |
| 2021-12-31 | 24059.32% |
| 2021-09-30 | -13096.68% |
| 2021-06-30 | -2492.46% |
| 2021-03-31 | -13097.42% |
| 2020-12-31 | -13074.19% |
| 2020-09-30 | -1943.11% |
| 2020-06-30 | -7514.14% |
| 2020-03-31 | -6930.98% |
| 2019-12-31 | 0.00% |
